LUND, Sweden, April 28, 2017 /PRNewswire/ --
BONESUPPORT AB, an emerging leader in innovative injectable
bioceramic bone scaffolds to treat bone voids caused by trauma,
infection, disease or related surgery, announces the election of
Lennart Johansson to its Board of
Directors.
Mr Johansson has been a Senior Advisor at Patricia Industries AB
since 2015, and was previously Managing Director (Business
Development, Operating and Financial Investments) at Investor AB
(2006-2015). Before that, he was Partner and Chief Executive
Officer of Emerging Technologies ET AB. He is currently Board
Member of Swedish Orphan Biovitrum AB and Hi3G Access AB; Deputy
Board Member of Mölnlycke Health Care AB; and Chairman of Vectura
AB. Mr Johansson holds an MBA from the Stockholm School of Economics (1980).
Håkan Björklund, Chairman of BONESUPPORT, said: "We are pleased
to welcome Lennart to the BONESUPPORT Board. This is an exciting
period for the Company and we are confident that Lennart's
experience will be a valuable asset assisting us to achieve our
goals."
Mr Johansson added: "I very much look forward to working with
the BONESUPPORT management team and Board to help capitalize on the
Company's potential to become a global leader in the management and
treatment of bone disease via its unique
CERAMENT[Ⓡ] platform."
About BONESUPPORT™
BONESUPPORT has developed CERAMENT as an innovative range of
radiopaque injectable osteoconductive bioceramic products that have
a proven ability to heal defects by remodeling to host bone in six
to 12 months. Our products are effective in treating patients with
fractures and bone voids caused by trauma, infection, disease or
related surgery. Our lead product, CERAMENT BONE VOID FILLER (BVF)
addresses important issues facing health care providers, such as
avoiding hospital readmissions and revision surgery that result
from failed bone healing and infection caused by residual bone
voids. CERAMENT BVF is commercially available in the U.S., EU,
SE Asia and the Middle East.
CERAMENT's distinctive properties as a drug eluting material
have been validated in clinical practice by CERAMENT G and CERAMENT
V, the first CE-marked injectable antibiotic eluting bone graft
substitutes. These products provide local sustained delivery of
gentamicin and vancomycin, respectively. The local delivery feature
enables an initial high concentration of antibiotics to the bone
defect and then a longer sustainable dose above the minimal
inhibitory concentration (MIC) to protect bone healing and promote
bone remodeling.
CERAMENT G and CERAMENT V have demonstrated good results in
patients with problematic bone infections including osteomyelitis.
They are also used prophylactically in patients who are at risk for
developing infection. CERAMENT G and CERAMENT V are available in
the EU.
BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected
scientist who has been the President of various musculoskeletal
societies. BONESUPPORT's mission is to bring people with bone and
joint diseases back to an active life. The Company is based in
Lund, Sweden.
www.bonesupport.com
BONESUPPORT™ and CERAMENT™ are registered
trademarks.
Contact Information
Björn Westberg
Chief Financial Officer
+46-(0)-46-286-53-24
info@bonesupport.com
SOURCE BONESUPPORT AB